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Summary
Symptomatic slow-acting drugs for the treatment of osteoarthritis (SYSADOA; OA) are compounds which are prescribed as drugs in European
countries since many years, whereas they are sold as nutraceuticals in USA. In Europe, the publication of the EULAR Recommendations for
the Treatment of Knee OA in 2003 has listed oral chondroitin sulfate (CS) as evidence 1A and strength of recommendation A which represents
the highest level for a therapeutic strategy.
Symptomatic slow-acting drugs are intended to be used as ground therapy for OA; these compounds are not rapidly acting agents such as
Non Steroidal Anti-Inﬂammatory Drugs (NSAIDs), and their clinical efﬁcacy on algo-functional symptoms can only be demonstrated after
a couple of weeks of regular intake. Interestingly, once the administration is stopped, they do show carry-over effects of various durations,
from about 3 months with the oral formulations to 6e9 months with intra-articular formulations. The main rationale behind the use of the SY-
SADOA therapeutic class is the reduction of NSAIDs in the overall drug management of OA disease and therefore consequently to limit the
very signiﬁcant risks of upper Gastro-intestinal (GI) tract erosions, ulcers with bleeding and/or deleterious renal effects in elderly patients.
The evidence for clinical efﬁcacy of oral CS as a drug able to signiﬁcantly improve the algo-functional symptoms of OA disease does come
from a set of randomized clinical studies published a couple of years ago. Indeed, it was demonstrated that the drug was effective in knee and
ﬁnger OA, whereas previous data suggested that hip OA patients could also beneﬁt from it. In addition, oral CS supported the comparison with
NSAIDs such as diclofenac sodium in a medium/long-term clinical study in patients with knee OA. A dose-ﬁnding study in patients with knee
OA did provide strong data supporting the administration of 800 mg of CS orally which had nearly the same effects as 1200 mg/day, whereas
the use of a sequential 3 months administration mode, twice a year was also shown to provide the same results as a continuous treatment.
The good tolerability and safety aspects of oral CS were largely documented in these CTs. Taking these important points into account, we
deﬁnitively have enough clinical data available supporting the view that oral CS is a valuable and safe symptomatic treatment for OA disease.
More recent data based on a couple of previous trials and two pivotal studies do provide further evidence that oral CS does also have
structure-modifying effects in knee OA patients.
A couple of other compounds such as hyaluronan, diacerein, avocado and soya unsaponiﬁables, doxycycline have also been tested with
respect to their potential disease-modifying effects. Additional compounds including receptor activator of NF-kB (RANK) ligand inhibitors,
cathepsin K inhibitors, bisphosphonates are further assessed regarding their potential structure-modifying effect.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Symptomatic slow-acting drugs for the treatment of osteoar-
thritis (SYSADOA; OA) are compounds which are pre-
scribed as drugs in European countries since many years,
whereas they are sold as nutraceuticals in USA. In Europe,
the publication of the EULAR Recommendations for the
Treatment of Knee OA in 2003 has listed oral chondroitin
sulfate (CS) as evidence 1A and strength of recommenda-
tion A which represents the highest level for a therapeutic
strategy.
Symptomatic slow-acting drugs are intended to be used
as ground therapy for OA; these compounds are not rapidly
acting agents such as Non Steroidal Anti-Inﬂammatory
Drugs (NSAIDS) and their clinical efﬁcacy on algo-func-
tional symptoms can only be demonstrated after a couple
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S19administration is stopped, they do show carry-over effects
of various durations, from about 3 months with the oral for-
mulations to 6e9 months with intra-articular formulations.
The main rationale behind the use of the SYSADOA thera-
peutic class is the reduction of NSAIDs in the overall drug
management of OA disease and therefore consequently
to limit the very signiﬁcant risks of upper Gastro-intestinal
(GI) tract erosions, ulcers with bleeding and/or deleterious
renal effects in elderly patients.Oral CS as a SYSADOA
CS belongs to the oral SYSADOA and the substance
does have a delayed mode of action in OA which means
that the ﬁrst effects on pain and mobility can only be
assessed after a couple of weeks of therapy (2e3 weeks),
in sharp contrast with analgesics and NSAIDs, which do act
more rapidly (1e3 days). Importantly, when stopped after 3
months of continuous daily administration, CS will present
in most cases with a remanent effect which can last for
a couple of months in some cases, a feature which is never
observed with analgesics and NSAIDs, substances which
need to be continuously administered in order to provide
relief from pain and increased mobility in OA patients.
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is that oral CS is registered as a drug in many European
countries, whereas it is sold since many years as a prescrip-
tion-free and over the counter (OTC) substance in all drug-
stores in the USA. The differences between both markets
are obvious. The oral CS sold and used on the European
market has been fully registered as a drug, which means
that it had to fulﬁll severe criteria of quality and safety and
was fully analyzed regarding its pharmacotoxicologic char-
acteristics and industrial processing. These requirements
are not applied to the CS sold as OTC on the American
market. There is no doubt that the actual content of active
substance and its quality in various brands of CS sold on
the US market are not directly comparable with the CS at
disposal in the European countries, which might also ex-
plain why the results of the clinical trials might differ signif-
icantly between both North America and Europe.
We did recently perform a survey of the available ran-
domized clinical trials (RCTs) to assess the clinical efﬁcacy
and tolerability of oral CS and did choose to review the
evidence on the basis of the published literature which
was critically analyzed. The results of this review were pub-
lished in 20061. Brieﬂy, the authors did assess the effects of
oral CS on OA of the knee using the available outcome cri-
teria such as the Lequesne’s Algo-functional Index (AFI),
the Huskisson Visual Analog Scale for Pain, the Walking
Time, the Western Ontario MacMaster score (WOMAC)
Score as well as analyzing the safety and tolerability data.
Two independent reviewers did assess the methodologi-
cal quality of the studies according to the Delphi Criteria
List2, which consists of a set of nine criteria for quality
assessment from 1 (use of randomization) to 9 (use of an
intention-to-treat analysis). For each quality criterion, three
rating categories were available: yes, met criteria, no, did
not meet the criteria, and does not know. In addition, per-
centage agreement and Cohen’s Kappa statistic were cal-
culated with GRAPHPAD Software (Version 2002) and
were interpreted with Landis and Koch’s benchmarks for
assessing the agreement between the two raters3.
The literature search yielded 11 reports that met the basic
eligibility criteria of being an RCT which assessed the
effects of oral CS on knee OA. A total of 1443 patients
were included originating from France: Mazie`res et al.4;
Bourgeois et al.5; Conrozier, 19986; and L’Hirondel,
19927; Switzerland: Michel et al.8; Uebelhart et al.9; Uebel-
hart et al.10, and Uebelhart et al.11; Belgium: Malaise
et al.12; Hungary: Bucsi and Poor13; Tschech Republic:
Pavelka et al.14. Several varieties of CS were used (bovine,
shark, and avian) which also differed in dosage
(500e1200 mg/day), treatment time (3e24 months) and
mode of administration, daily continuously (3e24 months)
or intermittently (2 3 months).
The results of this survey exclusively taking RCTs into
account, 10 published in peer-reviewed journals and one
study not yet published, having the highest methodological
quality, can be qualiﬁed overall as very positive for CS as an
oral SYSADOA for the treatment of knee OA. Indeed, they
did prove that the long-term administration of oral CS is
safe,well tolerated and fully indicated to control the symptoms
of pain and increase the overall mobility of knee OA patients.Oral CS as a disease or structure-modifying
drug in osteoarthritis (SMOAD)
Oral CS was also checked by humans as a disease or
structure-modifying drug (SMOAD) in the treatment of OA.Using the same analytic method described above for the
RCTs concerning the symptomatic effects of oral CS, we
were able to identify a total of six published studies in which
the SMOAD effect was assessed as primary or secondary
evaluation outcome. These RCTs were performed in
patients suffering from knee and ﬁnger OA. The main idea
behind the potential SMOAD effect of oral CS is that the
drug might be able to modify the course of the OA disease,
may stop its progression and not only positively act on
symptoms and mobility of the OA patients.SMOAD EFFECT OF CS IN KNEE OAA total of three RCTs originating from Switzerland and
which did evaluate the chondroprotective aspects of oral
CS as primary or secondary outcome were available includ-
ing 462 knee OA patients. One study was a one-center
study8, whereas the two other studies9,10 were multicentric
and included OA patients from various countries (France,
Italy, and Belgium) as well. In addition, two treatment
modalities were used which differed in their administration
sequence. One study reported an intermittent treatment
schedule of oral CS of 2 3 months daily oral CS 800 mg
during 1 year9, whereas the two other studies used a treat-
ment schedule of oral CS 800 mg daily given continuously
for a total of 1210 vs 248 consecutive months.
Importantly, only one8 out of these three studies had dis-
ease-modifying effect as a primary outcome, whereas in the
two other ones this was a secondary outcome. The radio-
logical progression was assessed in all three studies using
the medial femoro-tibial joint space narrowing (JSN) mea-
sured with a digitalized analysis of high-quality knee
X-rays. The results of the digitized X-rays analysis of the
JSN were identical in these studies, originally shown in
the two earlier and conﬁrmed in the third one.
The newest Study on Osteoarthritis Progression
Prevention (STOPP) multicentric international study was
designed as a RCT with the aim to test the SMOAD effect
of oral CS 800 mg daily vs placebo during a 2-year survey
in a total of 600 symptomatic knee OA patients. The re-
cruitment of the OA patients who had to be symptomatic
was performed on the basis of a blinded knee X-rays anal-
ysis performed in the Lyon-Schuss view. Only those
patients who complied with the very strict inclusion criteria
were enrolled and followed for 2 years after having been
randomized to both CS or placebo (PBO) treatment
groups. The results were already partially presented in
some international meetings, but the publication is still in
preparation. The main outcome of the STOPP study was
the evolution of the medial femoro-tibial JSN over 2 years
of treatment with oral CS as compared to PBO and did
conﬁrm that oral CS was able to signiﬁcantly stabilize
the JSN whereas PBO did not. A recent survey of the
available RCTs to assess the structure-modifying effect
of oral was published in 200615.SMOAD EFFECT OF CS IN FINGER JOINT OAA total of two RCTs could be identiﬁed including a total
of 284 patients. Both studies were performed at the
Department of Rheumatology of the University of Ghent,
Belgium. A ﬁrst study was based on the use of a numerical
scoring system for the anatomical evolution of ﬁnger joint
OA developed by Verbruggen and Veys16. A total of 119
patients suffering from ﬁnger OA were included in this
RCT with primary outcome being SMOAD effect of oral
CS given 3 400 mg/day over a period of 3 years
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joints. The results of this study showed that in the CS
treated group of patients, there was a signiﬁcant decrease
in the number of patients with new erosive OA ﬁnger
joints17,18. Two additional studies were conducted by
Verbruggen et al.19 to assess the progression of ﬁnger
OA using different Disease Modyfying Anti-Osteoarthritic
Drugs (DMOADs) (polysulfated chondroitin sulfate (CPS)
and CS) including oral CS 3 400 mg daily for a total du-
ration of 3 years. In this study, the 34 patients treated with
oral CS presenting with the classical OA anatomical
lesions presented with less progressive evolution with
both CPS and oral CS. In addition, fewer patients of both
CPS and oral CS treated groups developed erosive OA
of the ﬁnger joints. Even if additional studies are needed,
the SMOAD effect of oral CS in ﬁnger OA was clearly
demonstrated in these studies.Meta-analyses on CS in OA
Before the last meta-analysis of Reichenbach et al.20
was published, two other ones were available. Based on
data originating from published studies available at the
time of the publication, both Leeb et al.21 and McAlindon
et al.22 did provide some positive effects (moderate to
large) of oral CS on the relief of painful symptoms in OA
patients.
The latest published meta-analysis by Reichenbach
et al.20 did provide some more critical insights in the effects
of oral CS in OA pain. The authors did analyze 20 trials in-
cluding a total of 3846 patients originating from randomized
and quasi-randomized published studies focusing on pain
relief in patients suffering from knee and hip OA as well.
The authors did ﬁnd for CS a pooled effect size of 0.75
(95% conﬁdence interval [CI], 0.99e0.50) corresponding
to a large symptomatic effect of the substance. This very
positive result deﬁnitively goes along with the previous pub-
lished meta-analyses, but the ﬁnal interpretation of the
authors was surprisingly negative about a symptomatic
effect of the substance. It is worth noting that this meta-
analysis presented with numerous bias and methodological
problems which were also addressed as sound critics by
some experts in the ﬁeld of OA therapy who wrote letters
to the Editor.
The only way to solve the problem raised by this contro-
versial publication and to become a clear picture of the
effects of oral CS in OA patients would be to perform
a high-quality new meta-analysis based on the raw data
of the RCTs on CS and not based on the extracted data
from the publications which are always incomplete.Conclusion
Based upon published peer-reviewed RCTs and all avail-
able meta-analyses, oral CS has proven efﬁcacy in symp-
tomatic knee OA and structural-modifying effects in ﬁnger
and knee OA. In addition, the tolerability and safety proﬁle
of the substance were found to be very favorable in all avail-
able RCTs performed. Additional work related to both the
symptomatic and the structure-modifying effects of oral
CS in OA patients is currently ongoing and should help to
further clarify the situation of the substance in this
indication.Conﬂict of interest
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